OneSkin Secures $20M Funding for Pioneering Skin Aging Research
Longevity-focused skincare company OneSkin has successfully closed its Series A funding round, raising a significant $20 million. This funding will be used to advance their groundbreaking research into skin aging. The investment round was spearheaded by Selva Ventures, with contributions from Unilever Ventures, PLUS Capital, and other noteworthy investors, including model Camila Alves McConaughey.
OneSkin, established by four Brazilian PhD scientists, has pioneered OS-01, the first-ever peptide with scientific proof of reversing the biological age of skin. This is achieved by preventing the accumulation of senescent cells, a significant factor in aging. Recently, the company earned a spot in Fast Company’s Most Innovative Companies of 2024.
“This investment will allow us to deepen our commitment to delivering efficacious peptides that modulate aging at the cellular level,” stated Dr. Carolina Oliveira, OneSkin’s Co-Founder and CEO. The funding will expedite research into new formulations and broaden the company’s direct-to-consumer reach in the burgeoning $600 billion longevity market.
- Company: OneSkin
- Funding: $20 million
- Lead Investor: Selva Ventures
- Product: OS-01
- CEO: Dr. Carolina Oliveira